These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. ASXL1/2 mutations and myeloid malignancies. Medina EA; Delma CR; Yang FC J Hematol Oncol; 2022 Sep; 15(1):127. PubMed ID: 36068610 [TBL] [Abstract][Full Text] [Related]
43. A common ancestry for BAP1 and Uch37 regulators. Sanchez-Pulido L; Kong L; Ponting CP Bioinformatics; 2012 Aug; 28(15):1953-6. PubMed ID: 22645167 [TBL] [Abstract][Full Text] [Related]
44. The Functions and Mechanisms of PR-DUB in Malignancy. Cao L; Li R; Wu X Front Mol Biosci; 2021; 8():657150. PubMed ID: 33796551 [TBL] [Abstract][Full Text] [Related]
45. MBD5 and MBD6 stabilize the BAP1 complex and promote BAP1-dependent cancer. Tsuboyama N; Szczepanski AP; Zhao Z; Wang L Genome Biol; 2022 Sep; 23(1):206. PubMed ID: 36180891 [TBL] [Abstract][Full Text] [Related]
46. Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation. Nagase R; Inoue D; Pastore A; Fujino T; Hou HA; Yamasaki N; Goyama S; Saika M; Kanai A; Sera Y; Horikawa S; Ota Y; Asada S; Hayashi Y; Kawabata KC; Takeda R; Tien HF; Honda H; Abdel-Wahab O; Kitamura T J Exp Med; 2018 Jun; 215(6):1729-1747. PubMed ID: 29643185 [No Abstract] [Full Text] [Related]
47. Targeting lysine demethylase 6B ameliorates ASXL1 truncation-mediated myeloid malignancies in preclinical models. Ge G; Zhang P; Sui P; Chen S; Yang H; Guo Y; Rubalcava IP; Noor A; Delma CR; Agosto-Peña J; Geng H; Medina EA; Liang Y; Nimer SD; Mesa R; Abdel-Wahab O; Xu M; Yang FC J Clin Invest; 2024 Jan; 134(1):. PubMed ID: 37917239 [TBL] [Abstract][Full Text] [Related]
48. Asxl1 C-terminal mutation perturbs neutrophil differentiation in zebrafish. Fang X; Xu S; Zhang Y; Xu J; Huang Z; Liu W; Wang S; Yen K; Zhang W Leukemia; 2021 Aug; 35(8):2299-2310. PubMed ID: 33483612 [TBL] [Abstract][Full Text] [Related]
49. Generation and Characterization of Induced Pluripotent Stem Cells Carrying An ASXL1 Mutation. Wang W; Zhang X; Li Y; Shen J; Li Y; Xing W; Bai J; Shi J; Zhou Y Stem Cell Rev Rep; 2024 Oct; 20(7):1889-1901. PubMed ID: 38884929 [TBL] [Abstract][Full Text] [Related]
50. Molecular Regulation of the Polycomb Repressive-Deubiquitinase. Reddington CJ; Fellner M; Burgess AE; Mace PD Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33105797 [TBL] [Abstract][Full Text] [Related]
51. The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia. Dkhissi F; Aggoune D; Pontis J; Sorel N; Piccirilli N; LeCorf A; Guilhot F; Chomel JC; Ait-Si-Ali S; Turhan AG Exp Hematol; 2015 Sep; 43(9):775-80. PubMed ID: 26118501 [TBL] [Abstract][Full Text] [Related]
52. The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model. Hsu YC; Chiu YC; Lin CC; Kuo YY; Hou HA; Tzeng YS; Kao CJ; Chuang PH; Tseng MH; Hsiao TH; Chou WC; Tien HF J Hematol Oncol; 2017 Jul; 10(1):139. PubMed ID: 28697759 [TBL] [Abstract][Full Text] [Related]
53. Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification. Uni M; Masamoto Y; Sato T; Kamikubo Y; Arai S; Hara E; Kurokawa M Leukemia; 2019 Jan; 33(1):191-204. PubMed ID: 29967380 [TBL] [Abstract][Full Text] [Related]
54. B-cell intrinsic regulation of antibody mediated immunity by histone H2A deubiquitinase BAP1. Liang Y; Wang H; Seija N; Lin YH; Tung LT; Di Noia JM; Langlais D; Nijnik A Front Immunol; 2024; 15():1353138. PubMed ID: 38529289 [TBL] [Abstract][Full Text] [Related]
55. A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies. Inoue D; Fujino T; Sheridan P; Zhang YZ; Nagase R; Horikawa S; Li Z; Matsui H; Kanai A; Saika M; Yamaguchi R; Kozuka-Hata H; Kawabata KC; Yokoyama A; Goyama S; Inaba T; Imoto S; Miyano S; Xu M; Yang FC; Oyama M; Kitamura T Leukemia; 2018 Jun; 32(6):1327-1337. PubMed ID: 29556021 [TBL] [Abstract][Full Text] [Related]
56. [Role of ASXL1 mutations in hematological disorders]. Uni M Rinsho Ketsueki; 2019; 60(6):680-690. PubMed ID: 31281161 [TBL] [Abstract][Full Text] [Related]
58. Disruption of Gjini E; Jing CB; Nguyen AT; Reyon D; Gans E; Kesarsing M; Peterson J; Pozdnyakova O; Rodig SJ; Mansour MR; Joung K; Look AT Dis Model Mech; 2019 May; 12(5):. PubMed ID: 31064769 [TBL] [Abstract][Full Text] [Related]
59. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies. Yang H; Kurtenbach S; Guo Y; Lohse I; Durante MA; Li J; Li Z; Al-Ali H; Li L; Chen Z; Field MG; Zhang P; Chen S; Yamamoto S; Li Z; Zhou Y; Nimer SD; Harbour JW; Wahlestedt C; Xu M; Yang FC Blood; 2018 Jan; 131(3):328-341. PubMed ID: 29113963 [TBL] [Abstract][Full Text] [Related]
60. Loss of ASXL1 triggers an apoptotic response in human hematopoietic stem and progenitor cells. Hilgendorf S; Folkerts H; Schuringa JJ; Vellenga E Exp Hematol; 2016 Dec; 44(12):1188-1196.e6. PubMed ID: 27616637 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]